TABLE 2.

Analysis of cancer patient survival correlated to SLC6A14 expression.

Cancer Type	Prognosis	p Value	% 5-year survival		n		FPKM Best cut off	Median Expression
			High	Low	High	Low
Glioma	Not prognostic	0.0017	0*	11*	33	120	0.01	0
Thyroid	Not prognostic	0.17	92	93	159	342	0.53	0.17
Lung	Not prognostic	0.037	37	50	431	563	7.39	5.56
Colorectal	Not prognostic	0.085	81	57	128	469	5.2	1.71
Head and
Neck	Not prognostic	0.015	48	38	398	101	0.4	2.46
Stomach	Not prognostic	0.039	35	34	270	84	1.11	4.57
Liver	Not prognostic	0.0074	42	50	93	272	0.02	0
Pancreatic	Prognostic, high expression
	Unfavorable	0.00097	16	45	107	69	6.08	8.92
Urothelial	Not prognostic	0.16	38	43	126	280	0.65	0.23
Prostate	Not prognostic	0.013	100	96	233	261	1.27	1.12
Testis	Not prognostic	0.021	100	94	77	57	0.02	0.03
Breast	Not prognostic	0.031	83	80	508	567	0.29	0.26
Cervical	Not prognostic	0.036	61	72	178	113	2.17	4.08
Endometrial	Not prognostic	0.0010	81	63	392	144	0.07	0.38
Ovarian	Not prognostic	0.018	35	22	291	82	0.01	0.03
Melanoma	Not prognostic	0.27	36*	26*	28	74	0.56	0.04

The data from Protein Atlas (https://www.proteinatlas.org/ENSG00000268104-SLC6A14/pathology). FPKM, Fragments per Kilobase of exon per Million reads. * 3-year survival.